|
Patent landscape, scope, and claims: |
United States Drug Patent 6,936,612: Scope, Claims, and Landscape Analysis
Patent US 6,936,612, granted on August 23, 2005, covers a method for treating or preventing a viral infection. The patent is assigned to The Regents of the University of California. The patent's claims focus on the use of a specific class of compounds, exemplified by a pro-drug of 9-(2-phosphonomethoxypropyl)adenine (PMPA), which is marketed as tenofovir disoproxil fumarate (TDF). This patent has been a cornerstone in the intellectual property strategy for a significant antiviral medication.
What is the Primary Subject Matter of Patent US 6,936,612?
The patent claims a method for treating or preventing a viral infection in a subject. The core of the invention lies in the administration of a specific pharmaceutical composition.
- Composition: The composition contains a pro-drug of 9-(2-phosphonomethoxypropyl)adenine (PMPA). PMPA is a phosphonate nucleotide analogue.
- Pro-drug: The pro-drug is designed to enhance the oral bioavailability of PMPA. Tenofovir disoproxil is such a pro-drug.
- Viral Infections: The patent specifies treatment or prevention of infections caused by viruses including, but not limited to, Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV).
What are the Key Claims in Patent US 6,936,612?
The patent contains multiple claims that define the scope of protection. The primary claims are directed towards the method of treatment using the pro-drug.
- Claim 1: This independent claim defines a method for treating or preventing a viral infection in a subject. It specifies the administration of a pharmaceutical composition comprising a therapeutically effective amount of a pro-drug of 9-(2-phosphonomethoxypropyl)adenine (PMPA). The pro-drug is described as being capable of increasing the bioavailability of PMPA.
- Dependent Claims: Several dependent claims further refine the scope. These can include specifics on the type of pro-drug, the viral infection targeted, and the dosage. For instance, they may specify a particular ester form of the pro-drug or enumerate specific viruses.
- PMPA Structure: The patent provides the chemical structure of PMPA. PMPA's chemical formula is C9H14N5O4P, and its CAS registry number is 147127-20-6.
- Pro-drug Examples: While not exhaustive, the patent references the concept of esterified pro-drugs. Tenofovir disoproxil, a bis-POC ester of tenofovir, is a direct embodiment of this pro-drug concept and is the active pharmaceutical ingredient in Viread® (and a component in Truvada® and Atripla®).
What is the Technological Context and Significance of the Patented Invention?
The invention addresses the challenge of delivering PMPA, a potent antiviral agent, effectively to the body. PMPA itself has poor oral bioavailability.
- Bioavailability Challenge: Nucleotide and nucleoside analogues often face issues with absorption and transport across cell membranes.
- Pro-drug Strategy: The development of pro-drugs, such as tenofovir disoproxil, converts the active molecule into a more lipophilic form that can be better absorbed. Once inside the body, cellular esterases cleave the ester groups, releasing the active PMPA.
- Antiviral Mechanism: PMPA acts as a reverse transcriptase inhibitor. It gets phosphorylated intracellularly to its active diphosphate form, which competes with natural deoxynucleotide triphosphates for incorporation into viral DNA by reverse transcriptase. Upon incorporation, it causes chain termination, thereby inhibiting viral replication.
- Therapeutic Impact: This pro-drug approach enabled the development of oral medications for chronic viral infections like HIV and HBV, significantly improving patient outcomes and treatment adherence.
What is the Patent Landscape Surrounding US 6,936,612?
The patent landscape for US 6,936,612 is complex, involving subsequent patents on formulations, manufacturing processes, and combination therapies.
- Core Technology: US 6,936,612 covers the method of using the pro-drug of PMPA.
- Related Patents:
- Formulation Patents: Patents covering specific formulations of tenofovir disoproxil fumarate (TDF) exist, often detailing particle size, excipients, and stability.
- Combination Therapy Patents: Patents related to fixed-dose combinations of TDF with other antiretroviral drugs (e.g., emtricitabine in Truvada®) are crucial.
- Manufacturing Process Patents: Patents detailing specific synthetic routes for producing tenofovir disoproxil are also significant.
- Newer Pro-drugs: Patents on alternative pro-drugs of tenofovir, such as tenofovir alafenamide (TAF), represent advancements that aim for improved efficacy and safety profiles. TAF has a different chemical structure and delivery mechanism, leading to lower plasma tenofovir levels and potentially reduced renal and bone toxicity.
- Generic Entry: The expiry of key patents covering TDF and its formulations has led to the introduction of generic versions. However, patent litigation often involves challenges to validity and infringement claims, particularly for formulation or manufacturing process patents.
- Geographic Variations: Patent protection and enforcement vary by jurisdiction. While US 6,936,612 is central to the US market, parallel patents in other countries have governed global market access.
What are the Implications of Patent US 6,936,612 for Market Access and Competition?
This patent has had a profound impact on the market for HIV and HBV treatments.
- Exclusivity Period: The patent granted exclusive market rights for methods of treating viral infections using tenofovir disoproxil pro-drugs for its term.
- Brand Name Products: This exclusivity enabled the success of brand-name products such as Viread® (tenofovir disoproxil fumarate monotherapy) and combination pills like Truvada® (emtricitabine/tenofovir disoproxil fumarate) and Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate).
- Price and Revenue: The patent protection allowed for premium pricing and significant revenue generation for the patent holder and its licensees.
- Generic Competition: Upon patent expiry, generic manufacturers can enter the market, leading to price reductions and increased patient access.
- Innovation Incentives: The success of this patent likely spurred further investment in pro-drug development and antiviral research, including the development of TAF.
What is the Current Status and Future Outlook of Patent US 6,936,612?
Patent US 6,936,612 expired on August 23, 2022.
- Patent Expiry: The primary patent term has concluded. This means the method of treatment claimed in this patent is no longer protected by this specific patent.
- Market Dynamics: The expiry has facilitated the widespread availability of generic tenofovir disoproxil fumarate products.
- Continued Litigation: While the core patent has expired, related patents (e.g., on formulations, manufacturing, or newer pro-drugs like TAF) may still be in force and subject to ongoing legal challenges or licensing agreements.
- TAF as Successor: Tenofovir alafenamide (TAF) represents a next-generation pro-drug, protected by its own set of patents, offering an alternative with a potentially improved safety profile. The market is transitioning towards TAF-based regimens for many patients.
- R&D Focus: Future research and patenting efforts in this area focus on novel antivirals, improved drug delivery systems, and strategies to overcome resistance mechanisms.
Key Takeaways
Patent US 6,936,612 was foundational for the commercialization of tenofovir disoproxil fumarate (TDF), a critical antiviral agent. The patent claims a method for treating viral infections using a pro-drug of PMPA, enabling enhanced oral bioavailability. Its expiration has opened the market to generic competition, significantly impacting treatment accessibility and pricing for HIV and HBV. The landscape continues to evolve with newer pro-drugs like TAF and ongoing patent strategies for follow-on innovations.
Frequently Asked Questions
-
When did patent US 6,936,612 expire?
Patent US 6,936,612 expired on August 23, 2022.
-
What specific viral infections does the patent claim cover?
The patent claims cover treatment or prevention of viral infections including, but not limited to, Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV).
-
What is the active pharmaceutical ingredient (API) related to this patent?
The patent is related to a pro-drug of 9-(2-phosphonomethoxypropyl)adenine (PMPA). Tenofovir disoproxil is a key pro-drug embodiment.
-
What is the significance of a "pro-drug" in this patent?
A pro-drug is a pharmacologically inactive compound that is metabolized in the body into an active drug. In this case, the pro-drug form of PMPA was developed to improve its oral absorption and bioavailability.
-
Are there still patents protecting tenofovir treatments?
While US 6,936,612 has expired, other patents covering specific formulations, manufacturing processes, combination therapies, and newer tenofovir pro-drugs like tenofovir alafenamide (TAF) may still be in effect.
Citations
[1] The Regents of the University of California. (2005). United States Patent 6,936,612: Method of treating or preventing viral infection. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
